Ishara Investments LP 13F holdings, Q2 2026
Holdings as of June 30, 2026 · filings on SEC EDGAR · this is the latest filing on record
Ishara Investments LP disclosed 41 US equity positions worth $136.1m in its Q2 2026 13F filing. The largest position was ACAD at 7.6% of the reported book, followed by XERS and BMRN. Against the Q1 2026 filing, it opened 16 new positions, added to 13 and reduced 8 among the top 41 holdings.
What did Ishara Investments LP own in Q2 2026? Top 41 positions
| # | Stock | Sector | Weight | Value | Shares | Δ shares | vs Q1 2026 |
|---|---|---|---|---|---|---|---|
| 1 | ACAD ACADIA PHARMACEUTICALS INC | Healthcare | 7.6% | $10.4m | 410,000 | 233% | added |
| 2 | XERS XERIS BIOPHARMA HOLDINGS INC | Healthcare | 7.2% | $9.7m | 1,230,000 | 20% | added |
| 3 | BMRN BIOMARIN PHARMACEUTICAL INC | Healthcare | 6.0% | $8.2m | 143,500 | 75% | added |
| 4 | PRAX PRAXIS PRECISION MEDICINES I | Healthcare | 5.5% | $7.5m | 22,550 | 0% | held |
| 5 | RARE ULTRAGENYX PHARMACEUTICAL IN | Healthcare | 5.0% | $6.8m | 205,000 | 18% | added |
| 6 | AGIO AGIOS PHARMACEUTICALS INC | Healthcare | 4.5% | $6.1m | 164,000 | – | new |
| 7 | INSM INSMED INC | Healthcare | 4.0% | $5.5m | 51,250 | – | new |
| 8 | CRNXGBP CRINETICS PHARMACEUTICALS IN | 3.9% | $5.4m | 143,500 | – | new | |
| 9 | ZNTL ZENTALIS PHARMACEUTICALS INC | Healthcare | 3.7% | $5.0m | 1,025,000 | -17% | reduced |
| 10 | PCVX VAXCYTE INC | Healthcare | 3.5% | $4.8m | 82,000 | 43% | added |
| 11 | ANNX ANNEXON INC | Healthcare | 3.4% | $4.7m | 820,000 | 371% | added |
| 12 | TVTX TRAVERE THERAPEUTICS INC | Healthcare | 3.4% | $4.7m | 82,000 | -26% | reduced |
| 13 | TNXP TONIX PHARMACEUTICALS HLDG C | 3.2% | $4.3m | 338,250 | – | new | |
| 14 | BBIO BRIDGEBIO PHARMA INC | Healthcare | 3.1% | $4.3m | 57,400 | – | new |
| 15 | AXSM AXSOME THERAPEUTICS INC. | Healthcare | 2.9% | $4.0m | 16,400 | -60% | reduced |
| 16 | CTNM CONTINEUM THERAPEUTICS INC | 2.5% | $3.4m | 205,000 | 44% | added | |
| 17 | LXRX LEXICON PHARMACEUTICALS INC | Healthcare | 2.2% | $3.1m | 1,271,000 | 41% | added |
| 18 | KURA KURA ONCOLOGY INC | Healthcare | 2.2% | $3.0m | 276,750 | – | new |
| 19 | DBVT DBV TECHNOLOGIES S A | 2.2% | $3.0m | 184,500 | 80% | added | |
| 20 | GMAB GENMAB A/S | Healthcare | 2.1% | $2.8m | 102,500 | 25% | added |
| 21 | CYTK CYTOKINETICS INC | Healthcare | 2.1% | $2.8m | 32,800 | – | new |
| 22 | MLYS MINERALYS THERAPEUTICS INC | Healthcare | 2.0% | $2.8m | 102,500 | 25% | added |
| 23 | SLN SILENCE THERAPEUTICS PLC | 1.8% | $2.4m | 55,350 | -61% | reduced | |
| 24 | NUVB NUVATION BIO INC | Healthcare | 1.5% | $2.1m | 369,000 | – | new |
| 25 | WVE WAVE LIFE SCIENCES LTD | Healthcare | 1.4% | $1.9m | 328,000 | – | new |
| 26 | NKTR NEKTAR THERAPEUTICS | Healthcare | 1.4% | $1.9m | 26,650 | – | new |
| 27 | SRRK SCHOLAR ROCK HLDG CORP | Healthcare | 1.2% | $1.7m | 30,750 | -46% | reduced |
| 28 | ELVN ENLIVEN THERAPEUTICS INC | Healthcare | 1.2% | $1.7m | 32,800 | – | new |
| 29 | ALNY ALNYLAM PHARMACEUTICALS INC | Healthcare | 1.1% | $1.5m | 5,125 | 0% | held |
| 30 | BEAM BEAM THERAPEUTICS INC | Healthcare | 1.0% | $1.4m | 41,000 | -29% | reduced |
| 31 | SION SIONNA THERAPEUTICS INC | Healthcare | 1.0% | $1.4m | 123,000 | 150% | added |
| 32 | ORIC ORIC PHARMACEUTICALS INC | Healthcare | 1.0% | $1.3m | 123,000 | 20% | added |
| 33 | NEWAMSTERDAM PHARMA COMPANY | 0.9% | $1.3m | 36,900 | 0% | held | |
| 34 | VRTX VERTEX PHARMACEUTICALS INC | Healthcare | 0.9% | $1.2m | 2,460 | – | new |
| 35 | SPRY ARS PHARMACEUTICALS INC | Healthcare | 0.8% | $1.1m | 143,490 | – | new |
| 36 | MNPR MONOPAR THERAPEUTICS INC | 0.8% | $1.1m | 12,300 | – | new | |
| 37 | ERAS ERASCA INC | Healthcare | 0.6% | $751.1k | 41,000 | – | new |
| 38 | VERA VERA THERAPEUTICS INC | Healthcare | 0.3% | $439.8k | 10,250 | -88% | reduced |
| 39 | IMTX IMMATICS N.V | Healthcare | 0.2% | $311.5k | 30,750 | -80% | reduced |
| 40 | MREO MEREO BIOPHARMA GROUP PLC | Healthcare | 0.2% | $244.2k | 768,750 | – | new |
| 41 | GOSS GOSSAMER BIO INC | Healthcare | 0.1% | $135.0k | 820,000 | 0% | held |
Weights are shares of the reported long US equity book (options excluded). Values are as filed, normalised to whole dollars. Share changes compare against the immediately preceding filing only.